EC Microbiology

Introduction: Imaging techniques such as computed tomography (CT) can provide unique information about any region of the body. It is an essential aid in detecting tumors and evaluating their size and growth over a period of time. Liver tumors/Hepatocellular carcinoma are difficult lesions to detect, and because of the presence of some isodense areas, false negative results can be expected, yet computed tomography is largely used for the evaluation of such tumors. With the advancement in technology, it now becomes easier to evaluate these tumors since this modality is important to assess those patients who are likely or not to get benefit from anticancer treatment. The Liver Imaging Reporting and Data System (LI-RADS) is one system that was released in 2011 to standardize the interpretation, development, and increased risk of hepatocellular tumors. A recent version of this system was released in 2018, which is LI-RADS v2018.

Aim of the Study: The aim of the present review is to understand the role of computed tomography in diagnosing and assessing the liver tumors.

Methodology: The review is a comprehensive research of PUBMED since the year 1992 to 2020.

Conclusion: Computed tomography-guided LI-RADS v2018 system provides data for the standardized interpretation of findings in patients at risk for hepatocellular. With the advent of advanced research in recent times, research into quantitative imaging and functional imaging has created a new way and opportunity in liver imaging and assessment of tumors. Certain parameters can be suggestive of expected liver tumors and could serve as early predictors of response.

Keywords: Hepatocellular Carcinoma; Computed Tomography

1. Elsayes KM., et al. “LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance”. Journal of Hepatocellular Carcinoma 6 (2019): 49.
2. Chernyak V., et al. “LI-RADS® algorithm: CT and MRI”. Abdominal Radiology 1 (2018): 111-126.
3. Santillan C. “CT and MRI of the liver for hepatocellular carcinoma”. Hepatoma Research 6 (2020): 63.
4. Ichikawa T., et al. “Hypervascular hepatocellular carcinoma: can double arterial phase imaging with multidetector CT improve tumor depiction in the cirrhotic liver?”. American Journal of Roentgenology 3 (2002): 751-758.
5. Choi JY., et al. “CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects”. Radiology3 (2014): 635.
6. Kielar AZ., et al. “An update for LI-RADS: version 2018. Why so soon after version 2017?” Journal of Magnetic Resonance Imaging: JMRI 6 (2019): 1990-1991.
7. Chernyak V., et al. “Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients”. Radiology3 (2018): 816.
8. Freeny PC., et al. “Hepatocellular carcinoma: reduced frequency of typical findings with dynamic contrast-enhanced CT in a non-Asian population”. Radiology1 (1992): 143-148.